SCHEMBL8237397

SCHEMBL8237397

Nc1cccc(N=C=O)c1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NOS1 P29475 1/20 0.48
CYP3A4 P08684 4/20 0.46
CASP1 P29466 1/20 0.46
RECQL P46063 1/20 0.46
TDP1 Q9NUW8 3/20 0.45
MAPK1 P28482 1/20 0.45
TRPA1 O75762 1/20 0.42
TSHR P16473 2/20 0.39
LMNA P02545 1/20 0.39
ALDH1A1 P00352 4/20 0.38
CA12 O43570 3/20 0.38
CA2 P00918 3/20 0.38
CA9 Q16790 3/20 0.38
CA1 P00915 2/20 0.38
CA14 Q9ULX7 2/20 0.38
CA7 P43166 1/20 0.38
CA4 P22748 1/20 0.38
MAOA P21397 1/20 0.37
SIGMAR1 Q99720 1/20 0.36
GABRA1 P14867 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10615043 0.84 TDP1 (0.54) NOS1CYP3A4TDP1MAPK1TRPA1
SCHEMBL27873 0.84 TDP1 (0.54) NOS1CYP3A4TDP1MAPK1TRPA1
SCHEMBL27621561 0.81 TDP1 (0.52) NOS1CYP3A4TDP1MAPK1TRPA1
SCHEMBL17494883 0.80 NOS1 (0.44) NOS1CYP3A4TDP1MAPK1TRPA1
Ethylene SCHEMBL10425506 0.79 TDP1 (0.50) NOS1CYP3A4TDP1MAPK1TRPA1
SCHEMBL8128359 0.79 CYP3A4 (0.58) NOS1CYP3A4CASP1RECQLTDP1
SCHEMBL8652139 0.79 CYP3A4 (0.58) NOS1CYP3A4CASP1RECQLTDP1
SCHEMBL30365208 0.77 TDP1 (0.48) CYP3A4TDP1MAPK1TRPA1TSHR
SCHEMBL894324 0.77 TDP1 (0.48) CYP3A4TDP1MAPK1TRPA1TSHR
SCHEMBL3690370 0.77 MAPK1 (0.41) CYP3A4TDP1MAPK1TRPA1TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117050072-B Pyrazolopyridine derivative and application thereof 沈阳药科大学 2024-05-17 CN disclosed
CN-117050072-A Pyrazolopyridine derivative and application thereof 沈阳药科大学 2023-11-14 CN disclosed
US-20100305113-A1 Substituted Imidazopyridazines as Lipid Kinase Inhibitors CAPRARO HANS-GEORG 2010-12-02 US disclosed
US-7576175-B2 Amino acid terminated diphenylurea derivatives; display high binding affinity, specificity, and stability; use in treating cancer, inflammatory diseases, and autoimmune diseases THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2009-08-18 US disclosed
US-7576175-B2 Amino acid terminated diphenylurea derivatives; display high binding affinity, specificity, and stability; use in treating cancer, inflammatory diseases, and autoimmune diseases THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2009-08-18 US disclosed
US-20060019900-A1 Alpha-4 beta-1 integrin ligands for imaging and therapy THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2006-01-26 US disclosed
US-20060019900-A1 Alpha-4 beta-1 integrin ligands for imaging and therapy THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2006-01-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060019900-A1 Alpha-4 beta-1 integrin ligands for imaging and therapy ITGA4, ITGB4, ITGA1 NOS1 2043/4885CYP3A4 3827/4885CASP1 840/4885
US-20100305113-A1 Substituted Imidazopyridazines as Lipid Kinase Inhibitors PI4KA, PIK3CA, PIK3CB NOS1 4236/4885CYP3A4 977/4885CASP1 3558/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.